{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:16:15Z","timestamp":1793042175865,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013795","name":"Fujian Medical University","doi-asserted-by":"publisher","award":["2024QH1307"],"award-info":[{"award-number":["2024QH1307"]}],"id":[{"id":"10.13039\/501100013795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018623","name":"Quanzhou City Science and Technology Program","doi-asserted-by":"publisher","award":["2025QZNY063"],"award-info":[{"award-number":["2025QZNY063"]}],"id":[{"id":"10.13039\/501100018623","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2025J011585"],"award-info":[{"award-number":["2025J011585"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.intimp.2026.117502","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:43:26Z","timestamp":1790797406000},"page":"117502","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["c-MET\/NF-\u03baB axis modulates PD-L1 and CCL22-mediated immune evasion and its inhibition enhances anti-PD-1 efficacy in non-small cell lung cancer"],"prefix":"10.1016","volume":"190","author":[{"given":"Lijin","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xihu","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyang","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rencai","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2026.117502_bb0005","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00408-025-00801-x","article-title":"Update 2025: management of non-small-cell lung cancer","volume":"203","author":"Jeon","year":"2025","journal-title":"Lung"},{"key":"10.1016\/j.intimp.2026.117502_bb0010","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1001\/jamaoncol.2021.4932","article-title":"Update of incidence, prevalence, survival, and initial treatment in patients with non\u2013small cell lung cancer in the US","volume":"7","author":"Ganti","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.intimp.2026.117502_bb0015","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.1158\/1078-0432.CCR-18-1538","article-title":"Immunotherapy in non-small cell lung cancer: facts and hopes","volume":"25","author":"Doroshow","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2026.117502_bb0020","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2026.117502_bb0025","doi-asserted-by":"crossref","first-page":"9621","DOI":"10.1200\/JCO.2020.38.15_suppl.9621","article-title":"Acquired resistance to PD-1 blockade in NSCLC","volume":"38","author":"Schoenfeld","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2026.117502_bb0030","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2174\/157436211795659955","article-title":"The hepatocyte growth factor receptor: structure, function and pharmacological targeting in cancer","volume":"6","author":"Cecchi","year":"2011","journal-title":"Curr. Signal Transduct. Ther."},{"key":"10.1016\/j.intimp.2026.117502_bb0035","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12943-022-01503-1","article-title":"Molecular mechanism(s) of regulation(s) of c-MET\/HGF signaling in head and neck cancer","volume":"21","author":"Raj","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.intimp.2026.117502_bb0040","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241290733","article-title":"Targeting the MET gene: unveiling therapeutic opportunities in immunotherapy within the tumor immune microenvironment of non-small cell lung cancer","volume":"16","author":"Ye","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.intimp.2026.117502_bb0045","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jtho.2022.10.015","article-title":"MET alterations in NSCLC-current perspectives and future challenges","volume":"18","author":"Remon","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.intimp.2026.117502_bb0050","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.2340\/1651-226X.2025.44344","article-title":"Prevalence, molecular characterization, and prognosis of c-Met protein overexpression in a real-world cohort of patients with non-squamous non-small cell lung cancer","volume":"64","author":"Bar","year":"2025","journal-title":"Acta Oncol."},{"key":"10.1016\/j.intimp.2026.117502_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2024.100451","article-title":"Unraveling the significance of MET focal amplification in lung cancer: integrative NGS, FISH, and IHC investigation","volume":"37","author":"Xiang","year":"2024","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.intimp.2026.117502_bb0060","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s11523-022-00918-6","article-title":"Mutational landscape and expression of PD-L1 in patients with non-small cell lung cancer harboring genomic alterations of the MET gene","volume":"17","author":"Fischer","year":"2022","journal-title":"Target. Oncol."},{"key":"10.1016\/j.intimp.2026.117502_bb0065","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa2002787","article-title":"Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer","volume":"383","author":"Wolf","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2026.117502_bb0070","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1001\/jamaoncol.2023.1962","article-title":"Tepotinib treatment in patients with MET exon 14-skipping non-small cell lung cancer: long-term follow-up of the VISION phase 2 nonrandomized clinical trial","volume":"9","author":"Mazieres","year":"2023","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.intimp.2026.117502_bb0075","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1200\/JCO.23.02363","article-title":"Vebreltinib for advanced non-small cell lung cancer harboring c-met exon 14 skipping mutation: a multicenter, single-arm, phase II KUNPENG study","volume":"42","author":"Yang","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2026.117502_bb0080","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/JCO.24.00720","article-title":"Telisotuzumab vedotin monotherapy in patients with previously treated c-met protein\u2013overexpressing advanced nonsquamous EGFR-wildtype non\u2013small cell lung cancer in the phase II LUMINOSITY trial","volume":"42","author":"Camidge","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2026.117502_bb0085","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","article-title":"Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the immunotarget registry","volume":"30","author":"Mazieres","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.intimp.2026.117502_bb0090","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1007\/s12094-024-03455-y","article-title":"Efficacy and safety analysis of immunotherapy in non-small cell lung cancer patients with MET alterations","volume":"26","author":"Wang","year":"2024","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.intimp.2026.117502_bb0095","doi-asserted-by":"crossref","DOI":"10.1007\/s12032-025-02641-4","article-title":"Tumor microenvironment: recent advances in understanding and its role in modulating cancer therapies","volume":"42","author":"Shah","year":"2025","journal-title":"Med. Oncol."},{"key":"10.1016\/j.intimp.2026.117502_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216894","article-title":"Unraveling the tumor microenvironment: insights into cancer metastasis and therapeutic strategies","volume":"591","author":"El-Tanani","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.intimp.2026.117502_bb0105","article-title":"The evolutionary trajectory and prognostic value of GITR+ Tregs reprogramed by tumor-intrinsic PD-1\/c-MET signaling in pancreatic cancer","volume":"12","author":"Han","year":"2025","journal-title":"Adv. Sci. (Weinh)"},{"key":"10.1016\/j.intimp.2026.117502_bb0110","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00109-022-02179-2","article-title":"C-met up-regulates the expression of PD-L1 through MAPK\/NF-\u03baBp65 pathway","volume":"100","author":"Xu","year":"2022","journal-title":"J. Mol. Med. (Berl)"},{"key":"10.1016\/j.intimp.2026.117502_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2020.100315","article-title":"c-met expression in renal cell carcinoma with bone metastases","volume":"25","author":"Silva Paiva","year":"2020","journal-title":"J. Bone Oncol."},{"key":"10.1016\/j.intimp.2026.117502_bb0120","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.02135","article-title":"HGF-MET signaling shifts M1 macrophages toward an M2-like phenotype through PI3K-mediated induction of Arginase-1 expression","volume":"11","author":"Nishikoba","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.117502_bb0125","doi-asserted-by":"crossref","first-page":"5031","DOI":"10.21037\/tlcr-2025-1036","article-title":"c-MET expression and immune landscape in locally advanced patients with non-small cell lung cancer undergoing radiochemotherapy and consolidative immunotherapy","volume":"14","author":"Ye","year":"2025","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.intimp.2026.117502_bb0130","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nri3175","article-title":"Coordinated regulation of myeloid cells by tumours","volume":"12","author":"Gabrilovich","year":"2012","journal-title":"Nat. Rev. Immunol."},{"issue":"Supplement","key":"10.1016\/j.intimp.2026.117502_bb0135","article-title":"EP.08B.02 the impact of C-met expression on the immune microenvironment and survival in locally advanced non-small cell lung cancer","volume":"19","author":"Xu","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.intimp.2026.117502_bb0140","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.cyto.2015.12.013","article-title":"The hepatocyte growth factor (HGF)-MET receptor tyrosine kinase signaling pathway: diverse roles in modulating immune cell functions","volume":"82","author":"Ilangumaran","year":"2016","journal-title":"Cytokine"},{"key":"10.1016\/j.intimp.2026.117502_bb0145","first-page":"1090","article-title":"Chinese expert consensus on MET immunohistochemistry detection and interpretation standards for non-small cell lung cancer(2023 version)","volume":"52","year":"2023","journal-title":"Zhonghua Bing Li Xue Za Zhi"},{"key":"10.1016\/j.intimp.2026.117502_bb0150","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S1470-2045(24)00270-5","article-title":"Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (Insight 2): a multicentre, open-label, phase 2 trial","volume":"25","author":"Wu","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.intimp.2026.117502_bb0155","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1200\/JCO.2018.77.7326","article-title":"Phase Ib\/II study of capmatinib (INC280) plus gefitinib after failure of epidermal growth factor receptor (EGFR) inhibitor therapy in patients with EGFR-mutated, MET factor-dysregulated non-small-cell lung cancer","volume":"36","author":"Wu","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2026.117502_bb0160","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1097\/TP.0000000000005463","article-title":"CCL22-expressing stem cell-derived islet grafts recruit regulatory T cells in mice","volume":"110","author":"Filatov","year":"2026","journal-title":"Transplantation"},{"key":"10.1016\/j.intimp.2026.117502_bb0165","first-page":"197","article-title":"High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients","volume":"27","author":"Park","year":"2012","journal-title":"Histol. Histopathol."},{"key":"10.1016\/j.intimp.2026.117502_bb0170","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/626578","article-title":"Soluble c-met is a reliable and sensitive marker to detect c-met expression level in lung cancer","volume":"2015","author":"Lv","year":"2015","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.intimp.2026.117502_bb0175","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241713077","article-title":"Real-world data on combined EGFR-TKI and crizotinib treatment for acquired and de novo MET amplification in patients with metastatic EGFR-mutated NSCLC","volume":"24","author":"Urbanska","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2026.117502_bb0180","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1186\/s12885-024-13163-z","article-title":"MET amplification correlates with poor prognosis and immunotherapy response as a subtype of melanoma: a multicenter retrospective study","volume":"24","author":"Cai","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.intimp.2026.117502_bb0185","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1093\/annonc\/mdy334","article-title":"PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers","volume":"29","author":"Sabari","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.intimp.2026.117502_bb0190","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s00262-024-03882-4","article-title":"Role of the HGF\/c-MET pathway in resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer","volume":"74","author":"Akli","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.intimp.2026.117502_bb0195","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jtho.2020.11.017","article-title":"Genetic heterogeneity of MET-aberrant NSCLC and its impact on the outcome of immunotherapy","volume":"16","author":"Kron","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.intimp.2026.117502_bb0200","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","article-title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors","volume":"18","author":"Doroshow","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.intimp.2026.117502_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113556","article-title":"First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations","volume":"199","author":"Blasi","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.intimp.2026.117502_bb0210","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20174287","article-title":"MET receptor tyrosine kinase regulates the expression of co-stimulatory and co-inhibitory molecules in tumor cells and contributes to PD-L1-mediated suppression of immune cell function","volume":"20","author":"Ahn","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2026.117502_bb0215","article-title":"Hepatocyte growth factor-mediated apoptosis mechanisms of cytotoxic CD8+ T cells in normal and cirrhotic livers","volume":"9","author":"Chen","year":"2023","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.intimp.2026.117502_bb0220","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.716469","article-title":"NF-\u03baB: at the borders of autoimmunity and inflammation","volume":"12","author":"Barnabei","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.117502_bb0225","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1038\/onc.2017.47","article-title":"MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer","volume":"36","author":"Bouillez","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.intimp.2026.117502_bb0230","doi-asserted-by":"crossref","first-page":"5620","DOI":"10.4049\/jimmunol.174.9.5620","article-title":"Differential regulation of CCL22 gene expression in murine dendritic cells and B cells","volume":"174","author":"Ghadially","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2026.117502_bb0235","doi-asserted-by":"crossref","first-page":"10918","DOI":"10.1038\/s41467-025-66985-1","article-title":"Pericytes orchestrate a tumor-restraining microenvironment in glioblastoma","volume":"16","author":"Braun","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2026.117502_bb0240","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1651730","article-title":"c-Met inhibitor NVP-BVU972 induces antiviral protection and suppresses NF-\u03baB-mediated inflammation","volume":"16","author":"Xie","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.117502_bb0245","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s13046-021-02055-w","article-title":"Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy","volume":"40","author":"Li","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926013500?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926013500?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:27:36Z","timestamp":1791466056000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926013500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":49,"alternative-id":["S1567576926013500"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117502","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"c-MET\/NF-\u03baB axis modulates PD-L1 and CCL22-mediated immune evasion and its inhibition enhances anti-PD-1 efficacy in non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117502","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"117502"}}